ADDENDUM

https://doi.org/10.1038/s41586-018-0722-x

Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A. Margolin, Sungjoon Kim, Christopher J. Wilson, Joseph Lehár, Gregory V. Kryukov, Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger, John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jané-Valbuena, Felipa A. Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying K. Yu, Jianjun Yu, Peter Aspesi Jr, Melanie de Silva, Kalpana Jagtap, Michael D. Jones, Li Wang, Charles Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey B. Gabriel, Gad Getz, Kristin Ardlie, Vivien Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael P. Morrissey, William R. Sellers, Robert Schlegel & Levi A. Garraway

Addendum to: *Nature* https://doi.org/10.1038/nature11003, published online 28 March 2012; addendum 28 November 2012.

The Supplementary Information of our original Letter (https://doi.org/10.1038/nature11003) and the Addendum published on 28 November 2012 (https://doi.org/10.1038/nature11735; hereafter referred to as 'first Addendum') contain all of the data used for our analyses. These data include normalized activity (growth inhibition) responses for every cell line at each dose for all 24 of the compounds and drugs tested. These activity values were calculated from replicated data points extracted from one or more experimental assay plates, and normalized using treated and untreated controls from the same plates; as detailed in the original Letter (see the original Supplementary Information 2, page 10), and in the first Addendum. In subsequent correspondence, readers expressed an interest in reproducing our experimental pre-processing, so we shared with them the raw Cell Titer Glo (CTG) data values from each experimental well. These data are now provided as a reference for future readers.

Supplementary Data 1 to this Addendum contains raw values from wells with cell lines growing under control (AC, positive active; NC, untreated negative) or drug-treated (SA, single-agent) conditions. Supplementary Data 1 contains two row entries per well (one with raw CTG readouts, and the other with calculated activity values), and each column contains descriptions or response values, as detailed in Table 1 of this Addendum. Only valid wells are included, so there may be missing concentrations from curves containing data that were flagged as 'invalid'. Compound and cell line names in Supplementary Data 1 are as they were originally captured, which in some cases may differ from names used in the Supplementary Tables of the original Letter and first Addendum. Calculated activity values may also differ in some cases from those in the original Letter, owing to subsequent quality-control call changes in our database since 2012. Chemical names can be reconciled using Table 2 of this Addendum, noting that 'sample-ID' denotes the 'ID-concept' of Table 2 with salt form and batch suffixes appended. Discrepant cell line names may be understood with reference to columns A, C and D of the 'All_Drug_response_data' sheet in supplementary data 1 from the 2015 CCLE and GDSC consortium paper[1].

We thank Jessie Ambrose and Vladimir Baranov for extracting and quality-checking the raw chemical response data in this Addendum. We also thank the reader who requested the raw data and assisted in quality-checking these results.

1. The Cancer Cell Line Encyclopedia Consortium & The Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. *Nature* **528**, 84–87 (2015).

Table 1 | Descriptions for key columns in Supplementary Data 1

Header	Description
CELL_LINE_NAME	Cell line name
MASTER_PLATE_NAME	Name of master plate for compound dispensing
PLATE_GROUP	Experimental batch identifier
ASSAY_PLATE_NAME	Barcode identifier for this experimental plate
DATE_CREATED	Date and time of experimental plate readout
LAYER_TYPE	CTG readout (RAW) or calculated activity (OUTPUT)
WELL_TYPE	Untreated (NC), positive (AC), or drug treated (SA)
COLUMN_ID	Column identifier for this experimental well
ROW_ID	Row identifier for this experimental well
COMPOUND	Sample-ID for the chemical used
CONCENTRATION	Compound concentration in micromoles
VALUE	Raw CTG readout value

CORRECTIONS & AMENDMENTS

Table 2 | Chemical name mappings

Name	ID-concept	Name-probe	Name-generic	Name-brand
paclitaxel	NVP-LEE850; NVP-BGT136; NVP-LLP829; CHIR167540	TL-139; BMS-181339; LSM-1102; MGI-GP; SW198621	paclitaxel	Taxol; Genexol; Abraxane
irinotecan	NVP-LBN777; CHIR169217	CPT-11; U-101440E; CPT11; LSM-2167; DQ-2805; NSC-616348; SW197790; SW199156	irinotecan	Camptosar; Campto; Topotecin
topotecan	NVP-LBN564; NVP-LBN816; CHIR158120; SN-38	SKF-104864; INOC-010; INX-0076; BRD-A36630025; 7-ethyl-10- hydroxycamptothecin; LSM-5662; E-89-001; NK-211; NSC-609699; SKF-S-104864-A; SW197557; SW199637	topotecan	Hycamtin; Evotropin; Topotecan; Hycamptin
panobinostat	NVP-LBH589	NVP-LBH589; LSM-4284; LBH-589	panobinostat	Faridak
L-685458	NVP-LLP590; NVP-AHK537; CGP055750	L-685458; L-682679; BRD-K87317732		
tanespimycin	NVP-LJM835; NVP-BAG500; NVP-LLP773; CHIR371658	17-AAG; CNF-1010; IPI-493; IPI-504; KOS-953; LSM-5870; BRD-K81473043; CP-127374; NSC-330507; NSC-704057	tanespimycin; retaspimycin; 17-allylaminogel-danamycin	
NVP-LBW242	NVP-LBW242; NVP-LDK934	CHEMBL1950720; SureCN2731929;NVP-LBW242; LBW242		
nutlin-3A	NVP-BEP453;	LSM-6351	nutlin-3A	
palbociclib	NVP-LCY393	PD-0332991; LSM-1071	palbociclib	
saracatinib	NVP-BHT496	AZD-0530; NSC-735464; KIN001-045; LSM-1032	saracatinib	
PLX-4720	NVP-LFL230; CHIR779209	PLX-4720; LSM-1049		
PD-0325901	NVP-LBW624; CHIR371086	PD-0325901; DB07046; CHEMBL447345; CHEMBL573579; CHEMBL573819; LSM-1101		
selumetinib	NVP-LFE158	AZD-6244; Arry-142886; LSM-1056; BRD-K57080016; ARRY-886	selumetinib	
NVP-RAF265	NVP-RAF265; HIR371265; HIR565852	CHIR-265; NVP-RAF265; LSM-1207		
nilotinib	NVP-AMN107; NVP-LOY196	NVP-AMN107; LSM-1099;AMN-107	nilotinib	Tasigna
NVP-TAE684	NVP-TAE684	NVP-TAE684; TAE-684; KIN001-017; LSM-1024		
crizotinib	NVP-LDQ718; NVP-BQK827	PF-2341066; KIN001-023; LSM-1027	crizotinib	Xalkori
erlotinib	NVP-XBX005; CHIR381147; CGP084057; CGP084057A	CP-258; OSI-774; RG-1415; Ro-50-8231; LSM-1097; CP-358774; NSC-718781; R-1415; SW198886	erlotinib	Tarceva
lapatinib	NVP-BCZ548	GW-2016; GW-572016F; GSK-572016; LSM-1051; W-572016; SW199101	lapatinib	Tykerb; Tyverb
dovitinib	NVP-TKI258; NVP-BAV666; CHIR154258	CHIR-258; TKI-258; NVP-TKI258; LSM-1127	dovitinib	
sandostatin	NVP-AES222; NVP-AEW541	NVP-AEW541; CC-535; LSM-1122; AEW541	sandostatin	
PHA-665752	NVP-BBD023	PHA-665752; SureCN140412; TCMDC-125885; LSM-1125		
vandetanib	NVP-AFD094; CHIR160840	ZD-6474; AZD-6474; LSM-1199	vandetanib	Caprelsa; Zactima
sorafenib	NVP-LBK294; CHIR156503	Bay-43-9006; NSC-724772; LSM-1008	sorafenib	Nexavar